After The Turkish-German couple introduce new vaccine Live music stocks rebound

Germany’s BioNTech and American Pfizer recently announced that their Covid-19 vaccination trials were 90 percent effective. But did you know the company’s founders are Turkish-Germans?

Everything we know about how COVID-19 (the disease caused by the novel coronavirus) is affecting the electronic music scene.

A Turkish-German husband-and-wife team have emerged as frontrunners in the race to market a vaccine against coronavirus, which would be an extraordinary achievement.

Turkish-born Ugur Sahin, 55, is CEO of German biotech firm BioNTech. He co-founded it with his wife and fellow board member Özlem Türeci, 53, and his former teacher, Prof Christoph Huber, an Austrian cancer expert.

Stocks surged following news on a promising vaccine trial carried out by the drugmaker Pfizer. The company revealed minimal, preliminary data from its clinical trial, but stated a potential vaccine—developed with German firm BioNTech—showed 90 percent effectiveness preventing coronavirus among volunteers who showed no sign of previous infection.

Shares in airlines, shopping malls, and other businesses that stand to benefit from a vaccine and eventual reopening surged. These included stocks related to live music, Billboard reported, a sector that has been hammered by global shutdowns. Live Nation was up nearly 21 points, while the German concert promoter CTS Eventim saw its share price rise 23.5% to $51.90.

Meanwhile, “stay-at-home” stocks like Zoom Video lost value. Zoom dropped 17.4% with the likes of Amazon and Netflix experiencing smaller losses.



More Stories
Gëinst, Sub Accent, Hydrangea and PRG/M on Accents Records